Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma

Idelalisib, a first-in-class oral inhibitor of phosphatidylinositol-3-kinase δ, has shown considerable antitumor activity as a monotherapy in recurrent indolent non-Hodgkin lymphoma (iNHL). To evaluate the safety and activity of idelalisib in combination with immunotherapy, chemotherapy, or both, 79...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Adv
Auteurs principaux: de Vos, Sven, Wagner-Johnston, Nina D., Coutre, Steven E., Flinn, Ian W., Schreeder, Marshall T., Fowler, Nathan H., Sharman, Jeff P., Boccia, Ralph V., Barrientos, Jacqueline C., Rai, Kanti R., Boyd, Thomas E., Furman, Richard R., Kim, Yeonhee, Godfrey, Wayne R., Leonard, John P.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2016
Sujets:
Clinical Trials and Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5737161/
https://ncbi.nlm.nih.gov/pubmed/29296805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016000976
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires